Edition:
United Kingdom

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

542.00GBp
4:35pm BST
Change (% chg)

22.00 (+4.23%)
Prev Close
520.00
Open
535.00
Day's High
543.50
Day's Low
521.00
Volume
1,659,604
Avg. Vol
820,143
52-wk High
784.00
52-wk Low
482.40

Chart for

About

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): £2,754.76
Shares Outstanding(Mil.): 386.36
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 82.78 30.95 32.75
EPS (TTM): 0.09 -- --
ROI: 3.10 14.84 14.38
ROE: 3.68 16.34 16.07

BRIEF-BTG full-year operating profit up 18 pct

* ADJUSTED BASIC EPS 1 32.9P UP 42 PERCENT Source text for Eikon: Further company coverage: (Reporting By London Bureau)

15 May 2018

U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

18 Jan 2018

U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

18 Jan 2018

UPDATE 1-U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK, Jan 18 A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc.

18 Jan 2018

Earnings vs. Estimates